LENZ THERAP
PharmaLENZ THERAP is a pharmaceutical company with 1 FDA-approved products.
FDA Novel Drug Designations
(2025)See 1 novel approval →
LENZ THERAP at a Glance
- Strong track record with 100% execution quality across 8 trials
- Fast trial execution (8 months median completion)
LENZ THERAP's Key Drugs
LENZ THERAP's core commercial portfolio centers on VIZZ — its most strategically important drugs approved in the last 15 years.
LENZ THERAP's Recent FDA Approvals
LENZ THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
LENZ THERAP's Therapeutic Areas
Disease areas where LENZ THERAP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LENZ THERAP Pipeline Snapshot
Active clinical trials for LENZ THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VIZZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-07-31
- Latest
- 2025-07-31
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges